Galectin Therapeutics Q1 net loss narrows to $5.1 million from $9.6 million
Galectin Therapeutics reported a first-quarter 2026 net loss applicable to common stockholders of $5.1 million, or $0.08 per share, down from $9.6 million, or $0.15 per share, a year earlier, mainly because research and development expenses fell to $2.2 million from $6.5 million. The company had $14.1 million of cash at March 31, 2026, plus $10 million left on a credit line from its chairman, and said this covers planned operations through May 2027, but its stockholders' deficit widened to $132.0 million.
Key points
- Net loss applicable to common stockholders was $5.1 million ($0.08 per share) for the quarter ended March 31, 2026, versus $9.6 million ($0.15 per share) a year earlier.
- Research and development expenses were $2.2 million, down from $6.5 million, which the company attributed mainly to timing of NAVIGATE trial expenditures.
- Cash and cash equivalents were $14.1 million at March 31, 2026, with $10 million remaining under a line of credit from the chairman of the board.
- Data from the NAVIGATE trial will be presented at EASL in May 2026, and an in-person Type-C meeting with the FDA is planned for the second quarter.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.